CaseTrail

Dura Pharmaceuticals, Inc. v. Michael Broudo

544 U.S. 336 · Decided April 19, 2005 · Supreme Court of the United States

Record summary. This page is generated from the Supreme Court Database’s coded data about the case. It describes who decided what, not the Court’s reasoning. Read the opinion itself before relying on it. Not legal advice.

At a glance

Dura Pharmaceuticals, Inc. v. Michael Broudo was decided on April 19, 2005 unanimously (9–0). The Court reversed the lower court's decision and remanded the case. Justice Stephen G. Breyer wrote the opinion of the Court. SCDB classifies its main issue as “Securities regulation” in the Economic Activity area.

Read the opinion

Case details

Citations
544 U.S. 336 · 125 S. Ct. 1627 · 161 L. Ed. 2d 577 · 2005 U.S. LEXIS 3478
Docket number
03-932
Decided
April 19, 2005
Argued
January 12, 2005
Decision type
Opinion of the Court (orally argued)
Disposition
Reversed and remanded
Outcome for petitioner
The petitioning party received a favorable disposition
Vote
9–0 (unanimous)
Majority opinion
Stephen G. Breyer
Opinion assigned by
William H. Rehnquist
How the case arrived
Certiorari
Legal provision
Securities Act of 1933, Securities Exchange Act of 1934, or Williams Act
Type of law
Federal statute
Decision direction (SCDB)
Conservative what this means

How the Justices voted

Full case caption

Dura Pharmaceuticals, Inc., et al. v. Michael Broudo et al.

SCDB identifiers: case 2004-040, docket 2004-040-01.

Other cases on “Securities regulation”

See all

Cases on the same legal provision: Securities Act of 1933, Securities Exchange Act of 1934, or Williams Act

Same Term, same area (Economic Activity)

See all

Source: Supreme Court Database, 2026 Release 01 (data file dated September 8, 2026). Imported into CaseTrail November 5, 2026. Coverage: decisions from the 1946 through 2025 Terms. Methodology · Report an error